Andreas Ward
Adult Health · Tallahassee, FLNPI 1891064176
Payments from drug & device makers
Across 177 payments — averaging $17.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$386
- Novartis$293
- Astellas Pharma US Inc$254
- Lilly USA, LLC$214
- Pfizer$191
- AbbVie$189
- plus $2K from 29 others
What the payments were for
- Food & beverage$3,083100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 22 | $386 |
| Novartis | 19 | $293 |
| Astellas Pharma US Inc | 16 | $254 |
| Lilly USA, LLC | 12 | $214 |
| Pfizer | 9 | $191 |
| AbbVie | 16 | $189 |
| Boehringer Ingelheim | 8 | $171 |
| E.r. Squibb & Sons, L.L.C. | 5 | $113 |
| Abbott | 6 | $107 |
| AstraZeneca | 7 | $101 |
| Bayer | 5 | $91 |
| Avanir Pharmaceuticals, Inc. | 6 | $88 |
| Global Blood Therapeutics, Inc. | 4 | $79 |
| Eisai Inc. | 4 | $77 |
| Jazz Pharmaceuticals Inc. | 3 | $77 |
| GSK | 4 | $75 |
| Kowa Pharmaceuticals America, Inc. | 4 | $55 |
| Otsuka America Pharmaceutical, Inc. | 3 | $53 |
| Sunovion Pharmaceuticals Inc. | 2 | $51 |
| Neurelis, Inc. | 2 | $40 |
| Phathom Pharmaceuticals, Inc. | 2 | $37 |
| Corcept Therapeutics | 2 | $37 |
| Johnson & Johnson | 2 | $33 |
| UCB, Inc. | 1 | $32 |
| Lundbeck LLC | 2 | $29 |
| Neurocrine Biosciences, Inc. | 1 | $28 |
| Merck | 2 | $26 |
| Urovant Sciences Inc | 1 | $24 |
| Daiichi Sankyo Inc. | 1 | $23 |
| Aimmune Therapeutics, Inc. | 1 | $23 |
| Sanofi | 1 | $20 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $18 |
| Teva Pharmaceuticals USA, Inc. | 1 | $16 |
| Amgen | 1 | $15 |
| Emmaus Medical, Inc. | 1 | $15 |
How this compares
$3,083 in reported general payments places this provider in the 80th percentile of 2,237 adult health providers in Florida.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 122 | $110,806 |
| JanuviaSitagliptin Phosphate | 143 | $52,668 |
| EliquisApixaban | 65 | $43,988 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 41 | $29,105 |
| JardianceEmpagliflozin | 61 | $28,616 |
| RybelsusSemaglutide | 17 | $26,650 |
| EntrestoSacubitril/Valsartan | 52 | $26,519 |
| FarxigaDapagliflozin Propanediol | 47 | $17,221 |
| LinzessLinaclotide | 23 | $13,122 |
| Lacosamide | 124 | $12,007 |
| Lagevrio (Eua)Molnupiravir | 12 | $11,146 |
| Acetaminophen-CodeineAcetaminophen With Codeine | 200 | $8,779 |
| MyrbetriqMirabegron | 14 | $8,552 |
| Xigduo XrDapaglifloz Propaned/Metformin | 26 | $7,903 |
| XareltoRivaroxaban | 12 | $7,500 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro | $214 | $110,806122 claims |
| MerckJanuvia, Lagevrio (Eua) | $26 | $63,814155 claims |
| PfizerEliquis | $191 | $43,98865 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta | $75 | $37,36968 claims |
| Boehringer IngelheimJardiance | $171 | $28,61661 claims |
| Novo NordiskRybelsus | $386 | $26,65017 claims |
| NovartisEntresto | $293 | $26,51952 claims |
| AstraZenecaFarxiga | $101 | $17,22147 claims |
| Johnson & JohnsonXarelto, Procrit | $33 | $14,40625 claims |
| AbbVieLinzess | $189 | $13,12223 claims |
| Astellas Pharma US IncMyrbetriq | $254 | $8,55214 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,237 adult health providers in Florida.
Other adult health in Tallahassee
- Patricia PagnottaMaitland$441K
- Carly KoelschSarasota$265K
- Norma SolisMiami$150K
- Ashley PontenbergWinter Park$136K
- Jeffrey HernandezMiami$122K
- Jamie JohnsonTampa$58K
- Jessica MangesClearwater$52K
- Sita SwamyOrlando$49K
- Alejandro Dela CruzOrlando$44K
- Cynthia OteroMaitland$31K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.